Elicio Therapeutics, Inc.
ELTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.05 | 0.01 | -0.00 |
| FCF Yield | -59.70% | -77.69% | -125.05% | -129.80% |
| EV / EBITDA | -1.41 | -1.10 | -0.83 | -0.41 |
| Quality | ||||
| ROIC | -256.24% | -186.17% | -138.15% | -340.37% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 95.64% |
| Cash Conversion Ratio | 0.71 | 0.93 | 0.79 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 167.03% |
| Free Cash Flow Growth | -13.42% | -43.48% | 6.67% | -44.72% |
| Safety | ||||
| Net Debt / EBITDA | -0.17 | 0.18 | -0.06 | -0.05 |
| Interest Coverage | -98.87 | -33.75 | -6.60 | -29.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.25 | 6.53 |
| Cash Conversion Cycle | -321.62 | -1,362.98 | 488.57 | -430.96 |